Share Twitter LinkedIn Facebook Email Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI Trials: NSCLC Trial Results In 2020, Primary Endpoint Is Overall Survival, Pancreatic Cancer Trial Results In 2020-2021.
Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023] Immunotherapy 2 Mins Read
O-RECIST, iRECIST, ImmunoPET: Assessing Treatment Response – Anna M. Wu, MD – MOASC [2023] Immunotherapy 1 Min Read